Amgen, US0311621009

Amgen stock: Dazodalibep data; EUR 419.08, down 1.82% pre-Xetra

Published on 11/17/2026 at 08:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen's dazodalibep delivered positive Phase 3 results in Sjögren's disease, adding a fresh clinical catalyst to the pipeline. On Xetra, the stock closed at EUR 426.85 on Monday, November 16, 2026.

Key points for Amgen investors

  • Both dazodalibep regimens met the primary endpoint in the Phase 3 OASIZ-301 study at Week 48.
  • The monthly regimen also improved patient-reported dryness, adding a further clinical data point for Amgen's pipeline.
Amgen, US0311621009, Illustration mit AI erstellt.

Amgen stock traded at 419.08 euros on Lang & Schwarz at 08:52 CET on Tuesday, November 17, 2026, 1.82% below the Xetra close of 426.85 euros on Monday, November 16.

Clinical data add pipeline focus

Amgen said on November 11 that both dosing regimens of dazodalibep met the primary endpoint at Week 48 in the Phase 3 OASIZ-301 study in Sjögren's disease. The 1,500-milligram regimen given every four weeks reduced the ESSDAI systemic disease activity score by 5.6 points from baseline, compared with 3.8 points for placebo. The 3,000-milligram regimen given every 12 weeks produced a 5.2-point reduction, also ahead of placebo. The monthly regimen additionally improved patient-reported dryness. The figures come from Amgen's investor relations release.

The update gives investors a new late-stage clinical data point as the company advances dazodalibep in an autoimmune disease area with substantial unmet need. The study results support continued attention on the program's development path.

US equities will trade in the broader context of the S&P 500.

More news and analyses on Amgen stock.

Disclaimer...
en | US0311621009 | AMGEN | boerse | 70525492 | bgmi